Peer-reviewed veterinary case report
Beta-defensin 3 kills Staph pseudintermedius from healthy and itchy
By Fazakerley, Jennifer et al.·Published in Veterinary dermatology·2010·The University of Liverpool School of Veterinary Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: In vitro antimicrobial efficacy of β-defensin 3 against Staphylococcus pseudintermedius isolates from healthy and atopic canine skin.
- Species:
- dog
Plain-English summary
A study found that a specific antimicrobial peptide called human beta-defensin 3 (hBD3) can effectively inhibit the growth of Staphylococcus pseudintermedius, a bacteria commonly found on the skin of dogs, whether they are healthy or have skin allergies (atopy). The research showed that hBD3 was able to stop bacterial growth at concentrations as low as 6.25 micrograms per milliliter. This suggests that hBD3 could be a useful treatment option for skin infections in dogs, as it works similarly for both healthy dogs and those with skin issues.
People also search for: dog skin infection treatment · Staphylococcus pseudintermedius in dogs · beta-defensin for dog skin problems
Abstract
β-Defensins (BDs) are highly conserved antimicrobial peptides important in innate defence against bacteria. β-Defensin 3 has a specific role in protecting the skin. This study quantified the minimal inhibitory concentration (MIC) of human (h)BD3 against Staphylococcus pseudintermedius isolates from atopic and healthy dogs. Single colony isolates (1 × 10(5) colony-forming units/mL log phase) were cultured with doubling dilutions of hBD3 in sodium phosphate buffer from 0.8 to 50 μg/mL at 37 °C for 2 h, before adding 100 μL of tryptone soy broth and incubating for a further 20 h. Bacterial growth was assessed as the mean optical density at 540 nm corrected for background. The median MIC was 12.5 μg hBD3/mL (range 3.125-25 μg/mL; n=22). Forty-five percent of the isolates were inhibited at ≤ 6.25 μg hBD3/mL, and 90% were inhibited at ≤ 12.5 μg hBD3/mL. Bacterial growth was not inhibited at ≤ 1.6 μg hBD3/mL. There were no significant differences in the inhibition by hBD3 of isolates from atopic (median MIC 12.5 μg/mL, range 6.25-25 μg/mL, n=14) and healthy dogs (median MIC 9.4 μg/mL, range 3.125-12.5 μg/mL, n = 8); from noninfected colonized sites (median MIC 12.5 μg/mL, range 3.125-25 μg/mL, n=16) and infected lesions (median MIC 9.4 μg/mL, range 6.25-12.5 μg/mL, n=6); or between sample sites (nose median MIC 12.5 μg/mL, range 6.25-25 μg/mL, n=5; perineum median MIC 12.5 μg/mL, range 3.125-25 μg/mL, n=7; ear median MIC 6.25 μg/mL, range 6.25-12.5 μg/mL, n=4; lesions median MIC 9.4 μg/mL, range 6.25-12.5 μg/mL, n=6). In conclusion, hBD3 inhibited the growth of canine S. pseudintermedius isolates in vitro irrespective of origin.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20492622/